With two Phase III programs ongoing for telavancin, Theravance Inc. found the antibiotic a global partner in Astellas Pharma Inc. through a deal worth up to $221 million. (BioWorld Today)

As lead product Flurizan is being tested in a Phase III trial for Alzheimer's disease, Myriad Genetics Inc. priced a public offering of its common stock to raise $129.5 million. (BioWorld Today)

Abgenix Inc.'s stock surged 37.7 percent Thursday following news that its EGFr inhibitor, panitumumab, significantly improved progression-free survival in a pivotal metastatic colorectal cancer study. (BioWorld Today)

Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. (BioWorld International)